MedTrace Logo

Multicenter Study Differentiated Thyroid Carcinoma

NCT00144079 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2006-05-09

No results posted yet for this study

Summary

The trial examines the clinical benefit of adjuvant external beam radiotherapy (RTx) for locally invasive differentiated carcinoma (TNM stages pT4 pN0/1/x M0/x; 5th ed. 1997) of the thyroid gland (DTC). Patients are treated with surgery (thyroidectomy and lymphadenectomy), radioiodine therapy (RIT) to ablate the thyroid remnant tissue, and TSH-suppressive L-thyroxine therapy with or without RTx after documented elimination of cervical I-131 uptake.

Conditions

  • Thyroid Neoplasms

Interventions

PROCEDURE

external beam radiotherapy

Sponsors & Collaborators

  • Deutsche Krebshilfe e.V., Bonn (Germany)

    collaborator OTHER

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Otmar Schober, Prof MD PhD · Department of Nuclear Medicine, Münster University Hospital, Münster, Germany

  • Henning Dralle, Prof MD · Dept. of General Surgery, University Halle-Wittenberg, Halle, Germany

  • Normann Willich, Prof MD · Department of Radiooncology, Münster University Hospital, Münster, Germany

  • Martin Biermann, MD · Dept. of Nuclear Medicine, Münster University Hospital

  • Burkhard Riemann, MD PhD · Dept. of Nuclear Medicine, Münster University Hospital

  • Andreas Schuck, MD PhD · Dept. of Radiooncology, Münster University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Completion
2010-01-31

Countries

  • Austria
  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00144079 on ClinicalTrials.gov